Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-γ

World Journal of Gastroenterology

Volumn 12, Issue 18, 2006, Pages 3006-3014

  Parvez, Mohammad Khalid ^a,b,c   Sehgal, Deepak ^b   Jameel, Shahid ^b   Sarin, Shiv Kumar ^c   Basir, Seemi Farhat ^a  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c G B PANT HOSPITAL   (India)

Author keywords

cccDNA; Hepatitis B virus (HBV); Interferon ; Lamivudine; Replicative intermediates

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RECOMBINANT GAMMA INTERFERON; VIRUS DNA;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA REPLICATION; DNA SYNTHESIS INHIBITION; DOT HYBRIDIZATION; ENZYME IMMUNOASSAY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; SOUTHERN BLOTTING; VIRUS CULTURE; VIRUS INHIBITION; VIRUS LOAD; VIRUS RECOMBINATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 33744526258     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i19.3006     Document Type: Article

References (44)

1. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999; 17: 1730-1733
2. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68
3. Shafritz DA, Lieberman HM. The molecular biology of hepatitis B virus. Annu Rev Med 1984; 35: 219-232
4. Hoofnagle JH, di Bisceghe AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356
5. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, Chan FK Hung LC, Lee YT, Tam JS, Lam CW, Sung JJ. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with Ianiivudine alone. Ann Intern Med 2005; 142: 240-250
6. Mutimer D, Naoumov N, Honkoop P, Marinos G, Ahmed M, de Man R, McPhillips P, Johnson M, Williams R, Elias E, Schalmn S. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998; 28: 923-929
7. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263
8. Schiff ER, Karayalcin S, Grimm I, Perillo RM, Dienstag J, Husa P, Schalm S, Crowther L, Sullivan M, Woessner M, McPhillips P, Brown N, and the international Lamivudine Investigator Group. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy (abstr). Hepatology 1998; 28: 388A
9. Porres JC, Mora I, Gutiez J, Bartolome J, Quiroga JA, Bas C, Compernolle C, Ordi J, Chocarro A, Carreno V. Antiviral effect of recombinant gamma interferon in chronic hepatitis B virus infection: a pilot study. Hepatogastroenterology 1988; 35: 5-9
10. Hayashi Y, Koike K. Interferon inhibits hepatitis B virus replication in a stable expression system of transfected viral DNA. J Virol 1989; 63: 2936-2940
11. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91
12. Di Bisceglie AM, Rustgi VK, Kassianides C, Lisker-Melman M, Park Y, Waggoner JG, Hoofnagle JH. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 1990; 11: 266-270
13. Ishihara H, Hayashi Y, Hara T. Aramaki Y. Tsuchiya S, Koike K. Specific uptake of asialofetuin-tacked liposomes encapsulating interferon-gamma by human hepatoma. cells and its inhibitory effect on hepatitis B virus replication. Biochem Biophys Res Commun 1991; 174: 839-845
14. Carreno V, Moreno A, Galiana F. Bartolome FJ. Alpha- and gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study. J Hepatol 1993; 17: 321-325
15. Bissett J, Eisenberg M, Gregory P, Robinson WS, Merigan TC. Recombinant fibroblast interferon and immune interferon for treating chronic hepatitis B virus infection: patients' tolerance and the effect on viral markers. J Infect Dis 1988; 157: 1076-1080
16. Marcellin P, Loriot MA, Boyer N, Martinot-Peignoux M, Degott C, Degos F, Brandely M, Lenfant B, Benhamou JP. Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. Hepatology 1990; 12: 155-158
17. Wang Y, Jacob JR, Menne S, Bellezza CA, Tennant BC, Gerin JL, Cote PJ. Interferon-gamma-associated responses to woodchuck hepatitis virus infection in neonatal woodchucks and virus-infected hepatocytes. J Viral Hepat 2004; 11: 404-417
18. Zhou DY, Cao YJ, Lin LY, Wang H, Huang JS. HBV resistant to lamivudine: experimental and clinical studies. Hepatobiliary Pancreat Dis Int 2002; 1: 519-522
19. Aloman C, Wands JR. Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy? Hepatology 2003; 38: 1584-1587
20. Xiong X, Yang H, Westland CE, Zou R, Gibbs CS. In vitro evaluation of hepatitis B virus polymerase mutations associated with fainciclovir resistance. Hepatology 2000; 31: 219-224
21. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-3507
22. Guptan RC, Thakur V, Kazim SN, Sarin SK. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients. J Gastroenterol Hepatol 2002; 17. 765-771
23. Delaney WE, Isom HC. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovinis. Hepatology 1998; 28: 1134-1146
24. Summers J, Smith PM, Horwich AL. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J Virol 1990; 64: 2819-2824
25. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987; 7: 2745-2752
26. Ourlin JC, Vilarent MJ, Daujat M, Harricane MC, Maurel P. Lipid-mediated gene transfer into normal adult human hepatocytes in primary culture. Methods Mol Biol 1998; 107. 371-380
27. Delaney WE, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, Isom HC, Bock CT, Marms MP, Trautwein C, Locarnini S. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001; 45: 1705-1713
28. Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, Wells FV, Chu CK, Gerin JL, Tennant BC, Korba BE. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 2001; 33: 254-266
29. Cova L, Zoulim F. Duck hepatitis B virus model in the study of hepatitis B virus. Methods Mol Med 2004; 96: 261-268
30. Bock CT, Schranz P, Schroder CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 1994; 8: 215-229
31. Civitico GM, Locarnini SA. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology 1994; 203: 81-89
32. Yang W, Summers J. Illegitimate replication of linear hepadnavirus DNA through nonhomologous recombination. J Virol 1995; 69: 4029-4036
33. Peters M, Davis GL, Dooley JS, Hoofnagle JH. The interferon system in acute and chronic viral hepatitis. Prog Liver Dis 1986; 8:453-467
34. Suri D, Schilling R, Lopes AR, Mullerova I, Colucci G, Williams R, Naoumov NV. Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J Hepatol 2001; 35: 790-797
35. Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000; 118: S83-103
36. Schiefke I, Klecker C, Maier M, Oesen U, Etzrodt G, Tannapfel A, Liebert UG, Berr F. Sequential combination therapy of HBe antigen-negative/ virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a. Liver Int 2004; 24: 98-104
37. Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000; 44: 551-560
38. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 94: 907
39. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, Sette A, Chisari FV. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181: 1047-1058
40. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, Rehermarm B, Del Prete G, Fiaccadori F, Ferrari C. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 1185-1194
41. Carman WF, Dourakis S, Karayiannis P, Crossey M, Drobner R, Thomas HC. Incidence of hepatitis B viraen-da, detected using the polymerase chain reaction, after successful therapy of hepatitis B virus carriers with interferon-alpha. J Med Virol 1991; 34: 114-118
42. Kuhns M, McNamara A, Mason A, Campbell C, Perrillo, R. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology 1992; 103: 1649-1656
43. Michalak TI. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. Immunol Rev 2000; 174: 98-111
44. Coffin CS, Michalak TI. Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. J Clin Invest 1999; 104: 203-212